Search Medical Condition
Please enter condition
Please choose location
Clear Trial Filters

Cervical Cancer Clinical Trials

A listing of Cervical Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (19) clinical trials

Chemoradiation-Induced Nausea and Emesis: Quality of Life

You will be interviewed about your perceptions of side effects that are related to your chemoradiation treatment. The interview will take about 20 minutes. You will be interviewed at the beginning of your chemoradiation treatment, 3 weeks after treatment starts, and at the first follow-up appointment after chemoradiation treatment ends. ...

Phase N/A

Ascertainment of Peripheral Blood or Saliva Samples for Genetic Epidemiology Studies of Familial Cancers

Patients can provide either a blood or saliva sample for the protocol. For blood samples, two tubes of blood (approximately 20 cc) will be drawn from the patient, utilizing a sterile technique. The tubes will be rocked so as to mix the blood with the additive (EDTA) in the tubes. ...

Phase N/A

Study of DNA Mutations in Predicting the Effect of External-Beam Radiation Therapy in Patients With Early Breast Cancer Localized Prostate Cancer or Gynecological Cancer

OBJECTIVES: Primary - To test the hypothesis that an association between common genetic variations, reported by single nucleotide polymorphisms (SNP) in relevant candidate genes, is associated with individual patient variability in normal tissue radiation response and toxicity. Secondary - To compare different clinical scoring systems for late normal tissue effects, ...

Phase N/A

Survivin Peptide Vaccination for Patients With Advanced Melanoma Pancreatic Colon and Cervical Cancer

As prognosis of advanced melanoma, pancreatic, colon and cervical cancer remains gloomy, new therapeutic modalities have to be developed to improve the patient´s clinical outcome. Immunotherapy, which targets tumor associated antigens of tumor cells or tumor stroma, is currently an intensively investigated, novel therapeutic option. As survivin is expressed both ...

Phase

Phase 1 / 2 Study of AGEN2034 in Advanced Tumors and Cervical Cancer

This is a Phase 1, open-label, 3 + 3 dose-escalation trial in subjects with metastatic or locally advanced solid tumors, with a consecutive Phase 2 expansion to evaluate efficacy in subjects with recurrent, unresectable, or metastatic (advanced) cervical cancer that has progressed after a platinum doublet.

Phase

Study of Nintedanib Plus Bevacizumab in Advanced Solid Tumors

This is an open-label, phase I dose-escalation study of Nintedanib combined with standard-dose Bevacizumab for advanced solid tumors in which Bevacizumab has an indication. The primary endpoints will be safety and tolerability of the drug combination and a determination of recommended Phase II dose for Nintedanib in combination with standard ...

Phase

HuMax-AXL-ADC Safety Study in Patients With Solid Tumors

The trial consists of two parts; a dose escalation part (phase I, first in- human (FIH)) and an expansion part (phase IIa). The dose escalation part has two dose escalation arms: the first arm investigates a once every 3 weeks (1Q3W) dose schedule and the second one investigates a three ...

Phase

Collection of Blood Bone Marrow Tumor or Tissue Samples From Patients With Cancer to Study Drug Resistance

Background: Ongoing research in the Experimental and Molecular Therapeutics Sections, NCI, requires the availability of blood, serum, tumor, hair follicle and tissue samples from patients with cancer. Resistance is the underlying cause of treatment failure, and may present as acquired or intrinsic drug resistance. Patients with cancer frequently present with ...

Phase N/A

Tisotumab Vedotin (HuMax -TF-ADC) Safety Study in Patients With Solid Tumors

The study is conducted in two parts. The dose escalation portion of the trial subjects are enrolled into cohorts at increasing dose levels of tisotumab vedotin (HuMax-TF-ADC) in 28 day treatment cycles. In the Cohort Expansion part of the trial, will further explore the recommended phase 2 dose of tisotumab ...

Phase

A Study of Patients Receiving High-Dose Rate Brachytherapy

BACKGROUND: - High dose rate brachytherapy (HDR) is a challenging technique utilized in many malignancies in order to deliver a high dose of radiation therapy to a tumor in a conformal fashion with a rapid dose fall-off with the objective of sparing normal surrounding tissue - HDR therapy has been ...

Phase